SAN DIEGO, CA--(Marketwire - February 02, 2010) - Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) announced that its majority owned subsidiary, Entest BioMedical Inc.
(OTCBB: ENTB) has initiated studies to support the Company's stem cell /
laser regenerative therapy for Chronic Obstructive Pulmonary Disease
(COPD).
According to a Company spokesperson, Entest has begun to research the
effects of Low Energy Near Infrared Radiation on cultured cells as a step
toward animal pre-clinical studies for the treatment of COPD. Studies will
be an extension of current Entest intellectual property covering
enhancement of stem cell growth and activity. Specific focus will be placed
on type II alveolar epithelial cells and related stem cells known to reside
in the lung.
Dr. Steve Josephs, Co-Principal Investigator for Entest, states, "We are
pleased with the progress of our
ENT-576 program which uses Low Level Laser (LLL) therapy for COPD as a
means of inhibiting inflammation and stimulating lung regeneration. We view
these studies as critical in determining the direction of our
pre-clinical and clinical research."
Entest's Chairman & CEO David Koos, stated, "According to the COPD
Foundation, every 4 minutes an American dies of COPD. It is estimated there
are over 24 million cases of COPD in the US, of which 12 million people
don't even know they have it. Our research represents hope for the future
in curing COPD."
About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTCBB: ENTB) is involved with the development of
stem cell therapy treatments for Chronic Obstructive Pulmonary Disease
(COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell
research applications for diabetes and other illnesses. The Company also is
involved with medical device development (including stem cell extraction
instrumentation). ENT-576 is a proprietary laser device currently under
development by Entest. The Company has filed 3 patent applications relating
to the treatment of COPD.
About Bio-Matrix Scientific Group:
Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is the majority owner of
Entest BioMedical Inc. BMSN is a biotechnology company headquartered in San
Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic
stem cell banks, three research laboratories, aseptic cellular/tissue class
10,000/100 processing lab, hematology, microbiology and flow cytometry
laboratories. David Koos serves as Chairman & CEO concurrently for BMSN and
ENTB.
Forward-looking statements:
This news release may contain forward-looking statements. Forward-looking
statements are inherently subject to risks and uncertainties, some of which
cannot be predicted or quantified. Future events and actual results could
differ materially from those set forth in, contemplated by, or underlying
the forward-looking statements. The risks and uncertainties to which
forward-looking statements are subject include, but are not limited to, the
effect of government regulation, competition and other material risks.
